We have studied a male patient with significant developmental delay, growth failure, hypotonia, girdle weakness, microcephaly, and multiple congenital anomalies including atrial (ASD) and ventricular (VSD) septal defects. Detailed cytogenetic and molecular analyses revealed three de novo X chromosome aberrations and a karyotype 46,Y,der(X)inv(X) (p11.4q11.2)inv(X)(q11.2q21.32∼q22.2)del(X)(q22.3q22.3) was determined. The three X chromosome aberrations in the patient include: a pericentric inversion (inv 1) that disrupted the Duchenne muscular dystrophy (DMD) gene, dystrophin, at Xp11.4; an Xq11.2q21.32∼q22.2 paracentric inversion (inv 2) putatively affecting no genes; and an interstitial deletion at Xq22.3 that results in functional nullisomy of several known genes, including a gene previously associated with X-linked nonsyndromic mental retardation, acyl-CoA synthetase long chain family member 4 (ACSL4). These findings suggest that the disruption of DMD and the absence of ACSL4 in the patient are responsible for neuromuscular disease and cognitive impairment.    

1.
Ahn AH, Kunkel LM: The structural and functional diversity of dystrophin. Nat Genet 3:283–291 (1993).
2.
Byers TJ, Lidov HGW, Kunkel LM: An alternative dystrophin transcript specific to peripheral nerve. Nat Genet 4:77–81 (1993).
3.
Cantagrel V, Lossi AM, Boulanger S, Depetris D, Mattei MG, Gecz J, et al: Disruption of a new X linked gene highly expressed in brain in a family with two mentally retarded males. J Med Genet 41:736–742 (2004).
4.
Chelly J, Mandel JL: Monogenic causes of X-linked mental retardation. Nat Rev Genet 2:669–680 (2001).
5.
Gecz J, Mulley J: Genes for cognitive function: developments on the X. Genome Res 10:157–163 (2000).
6.
Jonsson JJ, Renieri A, Gallagher PG, Kashtan CE, Cherniske EM, Bruttini M, et al: Alport syndrome, mental retardation, midface hypoplasia, and elliptocytosis: a new X linked contiguous gene deletion syndrome? J Med Genet 35:273–278 (1998).
7.
Leprêtre F, Delannoy V, Froguel P, Vasseur F, Montpellier C: Dissection of an inverted X(p21.3q27.1) chromosome associated with mental retardation. Cytogenet Genome Res 101:124–129 (2003).
8.
Longo I, Frints SG, Fryns JP, Meloni I, Pescucci C, Ariani F, et al: A third MRX family (MRX68) is the result of mutation in the long chain fatty acid-
9.
CoA ligase 4 (FACL4) gene: proposal of a rapid enzymatic assay for screening mentally retarded patients. J Med Genet 40:11–17 (2003).
10.
Meloni I, Vitelli F, Pucci L, Lowry RB, Tonlorenzi R, Rossi E, et al: Alport syndrome and mental retardation: clinical and genetic dissection of the contiguous gene deletion syndrome in Xq22.3 (ATS-MR). J Med Genet 39:359–365 (2002a).
11.
Meloni I, Muscettola M, Raynaud M, Longo I, Bruttini M, Moizard M-P, et al: FACL4, encoding fatty acid-CoA ligase 4, is mutated in nonspecific X-linked mental retardation. Nat Genet 30:436–440 (2002b).
12.
Muntoni F, Torelli S, Ferlini A: Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2:731–740 (2003).
13.
NCBI: National Center for Biotechnology Information. URL: http://www.ncbi.nlm.nih.gov/.
14.
OMIM: Online Mendelian Inheritance in Man. URL: http//www3.ncbi.nlm.nih.gov/OMIM/.
15.
Piccini M, Vitelli F, Seri M, Luis J, Galietta V, Moran O, et al: KCNE1-like gene is deleted in AMME contiguous gene syndrome: identification and characterization of the human and mouse homologs. Genomics 60:251–257 (1999).
16.
Robson WLM, Lowry RB, Leung AK: X-linked recessive nephritis with mental retardation, sensorineural hearing loss, and macrocephaly. Clin Genet 45:314–317 (1994).
17.
Ropers HH, Hamel BC: X-linked mental retardation. Nat Rev Genet 6:46–57 (2005).
18.
Sadoulet-Puccio HM, Kunkel LM: Dystrophin and its isoforms. Brain Pathol 6:25–35 (1996).
19.
Saito-Ohara F, Fukuda Y, Ito M, Agarwala KL, Hayashi M, Matsuo M, et al: The Xq22 inversion breakpoint interrupted a novel Ras-like GTPase gene in a patient with Duchenne muscular dystrophy and profound mental retardation. Am J Hum Genet 71:637–645 (2002).
20.
Stevenson RE, Schwartz CE: Clinical and molecular contributions to the understanding of X-linked mental retardation. Cytogenet Genome Res 99:265–275 (2002).
21.
Stevenson RE, Schwartz CE, Schroer RJ: X-linked Mental Retardation (Oxford University Press, Oxford 2000).
22.
Vervoort VS, Beachem MA, Edwards PS, Ladd S, Miller KE, de Mollerat X, et al: AGTR2 mutations in X-linked mental retardation. Science 296:2401–2403 (2002).
23.
Wheway JM, Yau SC, Nihalani V, Ellis D, Irving M, Splitt M, Roberts RG: A complex deletion- inversion-deletion event results in a chimeric IL1RAPL1-dystrophin transcript and a contiguous gene deletion syndrome. J Med Genet 40:127–131 (2003).
© 2006 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.